{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T11:37:22Z","timestamp":1768563442677,"version":"3.49.0"},"posted":{"date-parts":[[2023,5,1]]},"group-title":"Cardiovascular Medicine","reference-count":37,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Apparent treatment-resistant hypertension (aTRH) is defined as uncontrolled blood pressure (BP) despite using \u22653 antihypertensive classes or controlled BP while using \u22654 antihypertensive classes. Patients with aTRH have a higher risk for adverse cardiovascular outcomes compared to patients with controlled hypertension. Although there have been prior reports on the prevalence, characteristics, and predictors of aTRH, these have been broadly derived from smaller datasets, randomized controlled trials, or closed healthcare systems.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We extracted patients with hypertension defined by ICD 9 and 10 codes during 1\/1\/2015-12\/31\/2018, from two large electronic health record databases: the OneFlorida Data Trust (n=223,384) and Research Action for Health Network (REACHnet) (n=175,229). We applied our previously validated aTRH and stable controlled hypertension (HTN) computable phenotype algorithms and performed univariate and multivariate analyses to identify the prevalence, characteristics, and predictors of aTRH in these real-world populations.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The prevalence of aTRH in OneFlorida (16.7%) and REACHnet (11.3%) was similar to prior reports. Both populations had a significantly higher proportion of black patients with aTRH compared to those with stable controlled HTN. aTRH in both populations shared similar significant predictors, including black race, diabetes, heart failure, chronic kidney disease, cardiomegaly, and higher body mass index. In both populations, aTRH was significantly associated with similar comorbidities, when compared with stable controlled HTN.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In two large, diverse real-world populations, we observed similar comorbidities and predictors of aTRH as prior studies. In the future, these results may be used to improve healthcare professionals\u2019 understanding of aTRH predictors and associated comorbidities.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Clinical Perspective<\/jats:title>\n                  <jats:sec>\n                    <jats:title>What Is New?<\/jats:title>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>Prior studies of apparent treatment resistant hypertension have focused on cohorts from smaller datasets, randomized controlled trials, or closed healthcare systems.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>We used validated computable phenotype algorithms for apparent treatment resistant hypertension and stable controlled hypertension to identify the prevalence, characteristics, and predictors of apparent treatment resistant hypertension in two large, diverse real-world populations.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>What Are the Clinical Implications?<\/jats:title>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>Large, diverse real-world populations showed a similar prevalence of aTRH, 16.7% in OneFlorida and 11.3% in REACHnet, compared to those observed from other cohorts.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Patients classified as apparent treatment resistant hypertension were significantly older and had a higher prevalence of comorbid conditions such as diabetes, dyslipidemia, coronary artery disease, heart failure with preserved ejection fraction, and chronic kidney disease stages 1-3.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Within diverse, real-world populations, the strongest predictors for apparent treatment resistant hypertension were black race, higher body mass index, heart failure, chronic kidney disease, and diabetes.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:sec>\n                <\/jats:sec>","DOI":"10.1101\/2023.04.28.23289293","type":"posted-content","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T01:10:16Z","timestamp":1682989816000},"source":"Crossref","is-referenced-by-count":1,"title":["Characteristics and Predictors of Apparent Treatment Resistant Hypertension in Real-World Populations Using Electronic Health Record-Based Data"],"prefix":"10.64898","author":[{"given":"Eissa","family":"Jafari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5198-130X","authenticated-orcid":false,"given":"Rhonda M.","family":"Cooper-DeHoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4050-5030","authenticated-orcid":false,"given":"Mark B.","family":"Effron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9881-1017","authenticated-orcid":false,"given":"William R.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitrin W.","family":"McDonough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2023050411150922000_2023.04.28.23289293v1.1","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000066"},{"issue":"8","key":"2023050411150922000_2023.04.28.23289293v1.2","first-page":"e93","article-title":"Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association","volume":"147","year":"2023","journal-title":"Circulation"},{"key":"2023050411150922000_2023.04.28.23289293v1.3","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000379"},{"key":"2023050411150922000_2023.04.28.23289293v1.4","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2013.140"},{"key":"2023050411150922000_2023.04.28.23289293v1.5","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2018-313599"},{"key":"2023050411150922000_2023.04.28.23289293v1.6","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000051"},{"key":"2023050411150922000_2023.04.28.23289293v1.7","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32834a8a42"},{"key":"2023050411150922000_2023.04.28.23289293v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.06.017"},{"key":"2023050411150922000_2023.04.28.23289293v1.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2002.02045.x"},{"key":"2023050411150922000_2023.04.28.23289293v1.10","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.03850"},{"key":"2023050411150922000_2023.04.28.23289293v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2014.03.003"},{"key":"2023050411150922000_2023.04.28.23289293v1.12","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.142"},{"issue":"1","key":"2023050411150922000_2023.04.28.23289293v1.13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamainternmed.2017.6015","article-title":"Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis","volume":"178","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"11","key":"2023050411150922000_2023.04.28.23289293v1.14","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jash.2016.08.008","article-title":"Prevalence of treatment-resistant hypertension and important associated factors-results from the Swedish Primary Care Cardiovascular Database","volume":"10","year":"2016","journal-title":"J Am Soc Hypertens"},{"key":"2023050411150922000_2023.04.28.23289293v1.15","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12410"},{"key":"2023050411150922000_2023.04.28.23289293v1.16","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.06487"},{"issue":"8","key":"2023050411150922000_2023.04.28.23289293v1.17","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/jch.12773","article-title":"Blood Pressure Control Provides Less Cardiovascular Protection in Adults With Than Without Apparent Treatment-Resistant Hypertension","volume":"18","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"11","key":"2023050411150922000_2023.04.28.23289293v1.18","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/pds.5095","article-title":"Optimizing identification of resistant hypertension: Computable phenotype development and validation","volume":"29","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"2023050411150922000_2023.04.28.23289293v1.19","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/jamia\/ocab221","article-title":"The OneFlorida Data Trust: a centralized, translational research data infrastructure of statewide scope","volume":"29","year":"2022","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"2023050411150922000_2023.04.28.23289293v1.20","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s12885-021-08067-1","article-title":"Understanding the patient journey to diagnosis of lung cancer","volume":"21","year":"2021","journal-title":"BMC Cancer"},{"key":"2023050411150922000_2023.04.28.23289293v1.21","doi-asserted-by":"publisher","DOI":"10.1136\/amiajnl-2014-002747"},{"issue":"2","key":"2023050411150922000_2023.04.28.23289293v1.22","doi-asserted-by":"crossref","first-page":"e14777","DOI":"10.2196\/14777","article-title":"Optimizing Antihypertensive Medication Classification in Electronic Health Record-Based Data: Classification System Development and Methodological Comparison","volume":"8","year":"2020","journal-title":"JMIR Med Inform"},{"key":"2023050411150922000_2023.04.28.23289293v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.07.038"},{"issue":"8","key":"2023050411150922000_2023.04.28.23289293v1.24","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1097\/HJH.0000000000002419","article-title":"Apparent treatment-resistant hypertension: characteristics and prevalence in a real-world environment of an integrated health system","volume":"38","year":"2020","journal-title":"J Hypertens"},{"key":"2023050411150922000_2023.04.28.23289293v1.25","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.12191"},{"key":"2023050411150922000_2023.04.28.23289293v1.26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.030189"},{"key":"2023050411150922000_2023.04.28.23289293v1.27","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.170308"},{"key":"2023050411150922000_2023.04.28.23289293v1.28","doi-asserted-by":"publisher","DOI":"10.3109\/08037051.2011.622983"},{"issue":"9","key":"2023050411150922000_2023.04.28.23289293v1.29","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1751-7176.2012.00653.x","article-title":"Relationship of resistant hypertension and treatment outcomes with total arterial compliance in a predominantly African American hypertensive cohort","volume":"14","year":"2012","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2023050411150922000_2023.04.28.23289293v1.30","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.01448"},{"issue":"6","key":"2023050411150922000_2023.04.28.23289293v1.31","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1161\/HYPERTENSIONAHA.116.08128","article-title":"Trends in Antihypertensive Medication Use Among US Patients With Resistant Hypertension, 2008 to 2014","volume":"68","year":"2016","journal-title":"Hypertension"},{"key":"2023050411150922000_2023.04.28.23289293v1.32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.19.2560"},{"key":"2023050411150922000_2023.04.28.23289293v1.33","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000084"},{"issue":"3","key":"2023050411150922000_2023.04.28.23289293v1.34","first-page":"213","article-title":"[Hypertension in black patients]","volume":"43","year":"2018","journal-title":"J Med Vasc"},{"key":"2023050411150922000_2023.04.28.23289293v1.35","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00550113"},{"issue":"3","key":"2023050411150922000_2023.04.28.23289293v1.36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1053\/j.ackd.2014.11.006","article-title":"Sodium retention and volume expansion in nephrotic syndrome: implications for hypertension","volume":"22","year":"2015","journal-title":"Adv Chronic Kidney Dis"},{"key":"2023050411150922000_2023.04.28.23289293v1.37","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.161486"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.04.28.23289293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:32:51Z","timestamp":1768505571000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.04.28.23289293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":37,"URL":"https:\/\/doi.org\/10.1101\/2023.04.28.23289293","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1093\/ajh\/hpad084","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,5,1]]},"subtype":"preprint"}}